CRONOS GROUP INC (CRON.CA) Fundamental Analysis & Valuation
TSX:CRON • CA22717L1013
3.39 CAD
-0.09 (-2.59%)
Last: Mar 12, 2026, 07:00 PM
This CRON.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 4 out of 10 to CRON. CRON was compared to 34 industry peers in the Pharmaceuticals industry. CRON has a great financial health rating, but its profitability evaluates not so good. CRON is valied quite expensively at the moment, while it does show a decent growth rate.
1. CRON.CA Profitability Analysis
1.1 Basic Checks
- CRON had negative earnings in the past year.
- In the past year CRON had a positive cash flow from operations.
- In the past 5 years CRON reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: CRON reported negative operating cash flow in multiple years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -0.79%, CRON is in the better half of the industry, outperforming 64.71% of the companies in the same industry.
- CRON has a Return On Equity of -0.86%. This is in the better half of the industry: CRON outperforms 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.79% | ||
| ROE | -0.86% | ||
| ROIC | N/A |
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CRON has a Gross Margin (42.81%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of CRON has grown nicely.
- CRON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
2. CRON.CA Health Analysis
2.1 Basic Checks
- CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CRON has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, CRON has more shares outstanding
- There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 7.14 indicates that CRON is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 7.14, CRON belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
- CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.14 |
ROIC/WACCN/A
WACC8.63%
2.3 Liquidity
- A Current Ratio of 19.59 indicates that CRON has no problem at all paying its short term obligations.
- CRON's Current ratio of 19.59 is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
- A Quick Ratio of 18.62 indicates that CRON has no problem at all paying its short term obligations.
- CRON has a better Quick ratio (18.62) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.59 | ||
| Quick Ratio | 18.62 |
3. CRON.CA Growth Analysis
3.1 Past
- The earnings per share for CRON have decreased strongly by -104.00% in the last year.
- Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 24.63%.
- Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 25.70% on average per year.
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%
3.2 Future
- CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -72.39% yearly.
- Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 0.19% on average per year.
EPS Next Y1714.91%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue Next Year37.98%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CRON.CA Valuation Analysis
4.1 Price/Earnings Ratio
- CRON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 38.61, CRON can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 61.76% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.82. CRON is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 38.61 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as CRON's earnings are expected to grow with 210.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y359.62%
EPS Next 3Y210.9%
5. CRON.CA Dividend Analysis
5.1 Amount
- CRON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CRON.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:CRON (3/12/2026, 7:00:00 PM)
3.39
-0.09 (-2.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners15.08%
Inst Owner ChangeN/A
Ins Owners6.34%
Ins Owner ChangeN/A
Market Cap1.28B
Revenue(TTM)146.59M
Net Income(TTM)-9.45M
Analysts82.22
Price Target4.72 (39.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.13%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)12.75%
Revenue beat(4)1
Avg Revenue beat(4)1.94%
Min Revenue beat(4)-4.49%
Max Revenue beat(4)12.75%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.47%
Revenue beat(16)6
Avg Revenue beat(16)-2.81%
PT rev (1m)0%
PT rev (3m)-7.5%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-9.53%
EPS NY rev (3m)-9.53%
Revenue NQ rev (1m)-10.78%
Revenue NQ rev (3m)-10.78%
Revenue NY rev (1m)7.09%
Revenue NY rev (3m)5.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 38.61 | ||
| P/S | 6.45 | ||
| P/FCF | N/A | ||
| P/OCF | 36.55 | ||
| P/B | 0.86 | ||
| P/tB | 0.93 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.09
Fwd EY2.59%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.09
OCFY2.74%
SpS0.53
BVpS3.92
TBVpS3.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.79% | ||
| ROE | -0.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.81% | ||
| FCFM | N/A |
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
F-Score7
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 183.09% | ||
| Cap/Sales | 17.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.59 | ||
| Quick Ratio | 18.62 | ||
| Altman-Z | 7.14 |
F-Score7
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)118.29%
Cap/Depr(5y)94.57%
Cap/Sales(3y)10.61%
Cap/Sales(5y)10.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
EPS Next Y1714.91%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%
Revenue Next Year37.98%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%
EBIT growth 1Y75.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year219.41%
EBIT Next 3Y74.89%
EBIT Next 5Y-8.2%
FCF growth 1Y-103.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.27%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON.CA FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRON.CA.
What is the valuation status of CRONOS GROUP INC (CRON.CA) stock?
ChartMill assigns a valuation rating of 2 / 10 to CRONOS GROUP INC (CRON.CA). This can be considered as Overvalued.
What is the profitability of CRON stock?
CRONOS GROUP INC (CRON.CA) has a profitability rating of 2 / 10.